small molecule

ZENBEXUS

IBERDOMIDE HYDROCHLORIDE

Loss of exclusivitySeptember 2039latest FDA-listed patent expiry
CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand nameZENBEXUS
Active ingredientIBERDOMIDE HYDROCHLORIDE
StrengthEQ 1MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2026
Marketing statusRX

Listed patents

PatentExpiresType
11529339September 2039use U-4598
RE50917October 2034use U-4598
RE49647October 2034product
9221788September 2033substance
9629849August 2033use U-4598
8518972June 2031substance, product
9828361February 2031substance, product

Regulatory exclusivity

CodeExpires
NCEAugust 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.